Every Form 4 that Gossamer Bio (GOSS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GOSS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOSS filings page.
Gossamer Bio, Inc. (GOSS) reported that executive officer Christian Waage, EVP, Tech Ops and Admin, received a grant of stock options covering 2,900,026 shares of common stock at an exercise price of $0.175 per share. The options expire on 2036-08-23 and vest based on future milestones and service conditions tied to FDA approval of seralutinib or, if approval is delayed, over time following the second anniversary of the grant date.
Gossamer Bio, Inc. (GOSS) reported a Form 4 for Chief Development Officer Caryn Peterson showing a grant of stock options for 5,800,051 shares of common stock on 2026-08-24, at an exercise price of $0.175 per share, expiring on 2036-08-23.
According to the vesting terms, 50% of the option vests upon FDA approval of seralutinib. The remaining 50% then vests in 24 equal monthly installments after that approval, subject to continued service. If FDA approval has not occurred within two years of the grant date, the entire option instead vests in 24 equal monthly installments starting two years after the grant date, also subject to continued service.
Gossamer Bio, Inc. (GOSS) reported that Chief Commercial Officer Robert Paul Smith Jr. received a stock option grant for 5,800,051 shares of common stock on August 24, 2026. The option has an exercise price of $0.175 per share and expires on August 23, 2036. According to the vesting terms, 50% of the shares vest upon FDA approval of seralutinib, and the remaining 50% vest in 24 equal monthly installments after that approval, subject to continuous service. If FDA approval has not occurred within two years of the grant date, vesting instead begins in 24 equal monthly installments starting two years after the grant date, also subject to continued service.
Gossamer Bio, Inc. (GOSS) reported that its COO/CFO, Bryan Giraudo, acquired derivative securities. A family trust received 25 Pre-Funded Warrants, each initially exercisable for Series A-1 non-voting convertible preferred stock at an exercise price of $0.0001 per share, with no expiration date. Each Series A-1 share is automatically convertible, upon stockholder approval under applicable Nasdaq rules for the related private placement, into common stock equal to $1,000 divided by $0.14, subject to beneficial ownership limitations.
Separately, Giraudo was granted a stock option over 5,800,051 shares of common stock at an exercise price of $0.175 per share, expiring on August 23, 2036. According to the vesting terms, 50% of the option vests upon FDA approval of seralutinib, and the remaining 50% vests in 24 equal monthly installments after that approval; if such approval has not occurred within two years of grant, vesting shifts to 1/24th monthly beginning two years after grant, in each case subject to his continuous service.
Gossamer Bio, Inc. (GOSS) reported that President & CEO Faheem Hasnain acquired two derivative awards. A family trust received 166 Pre-Funded Warrants exercisable at $0.0001 per share into Series A-1 preferred stock, which is automatically convertible after stockholder approval into common stock per a $1,000 ÷ $0.14 formula. Separately, Hasnain was granted 5,800,051 stock options for common stock at an exercise price of $0.175 per share, expiring in 2036, with vesting tied primarily to FDA approval of seralutinib or, failing that by two years after grant, a monthly time-based vesting schedule.
Gossamer Bio, Inc. director John D. Quisel received a grant of stock options covering 115,000 shares of common stock as board compensation. The options have an exercise price of $0.178 per share and expire on June 3, 2036.
The entire option grant becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, conditioned on his continued board service. This is a routine non-employee director award rather than an open-market share purchase or sale.
Gossamer Bio director Skye Drynan received a new stock option grant as part of board compensation. The award covers 115,000 options to buy Gossamer Bio common stock at an exercise price of $0.178 per share, expiring on June 3, 2036.
The option was granted under the company’s Non-Employee Director Compensation Program and represents 115,000 underlying shares following this transaction. All option shares vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, assuming continued board service through that date.
Gossamer Bio, Inc. director Daniel Thomas O received a stock option award for 115,000 shares of common stock. The option has a per-share exercise price of $0.1780 and expires on June 3, 2036. This grant was made under the company’s Non-Employee Director Compensation Program and represents compensation rather than an open-market purchase.
The entire option becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving on the board through that vesting date. Following this grant, he holds 115,000 stock options directly.
Gossamer Bio, Inc. director Russell J. Cox received a grant of stock options covering 115,000 shares of common stock at an exercise price of $0.178 per share. The award was made under the company’s Non-Employee Director Compensation Program.
The options become fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service on the board through that date. Following this grant, Cox holds stock options for 115,000 shares.
Gossamer Bio, Inc. director Sandra Milligan received a grant of stock options covering 115,000 shares of common stock. The options have an exercise price of $0.178 per share and expire on June 3, 2036. The award was made under the company’s Non-Employee Director Compensation Program and becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to her continued board service. Following this grant, she holds 115,000 stock options directly.
Gossamer Bio, Inc. director Nathan Steven D received a grant of stock options for 115,000 shares of common stock at an exercise price of $0.1780 per share. The options expire on June 3, 2036 and vest in full on the earlier of the first anniversary of the grant or the next annual stockholder meeting, subject to continued board service.
Gossamer Bio, Inc. reported that Chief Medical Officer Richard Aranda had a one-time repricing of certain outstanding stock options effective March 19, 2026. A series of existing options were surrendered back to the company and replaced with new options covering the same numbers of shares, but with a reduced exercise price of $0.45 per share.
According to the disclosure, all other terms and conditions of the repriced options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on his ongoing service with the company.
Gossamer Bio, Inc. executive Caryn Peterson, EVP of Regulatory Affairs, reported a one-time repricing of multiple stock option awards effective March 19, 2026. Previously granted options were surrendered back to the company and replacement options for the same share amounts were granted with a reduced exercise price of $0.45 per share. According to the disclosure, all other terms of these options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on her ongoing service.
Gossamer Bio Chief Commercial Officer option repricing: Gossamer Bio, Inc. adjusted stock option awards held by Chief Commercial Officer Robert Paul Smith Jr. Effective as of March 19, 2026, the company approved a one-time repricing of certain outstanding options, lowering their exercise price to $0.45 per share while keeping vesting schedules and terms unchanged. Two existing option grants for 562,500 and 572,000 shares of common stock were disposed of back to the issuer at prior exercise prices of $2.88 and $1.13 per share, and replacement options for the same respective share amounts were granted at the new $0.45 exercise price under the 2019 Incentive Award Plan.
Gossamer Bio, Inc. reported that President & CEO Faheem Hasnain had several existing stock option awards surrendered to the company and replaced as part of a one-time repricing effective on March 19, 2026. The repricing reduced the exercise price of each affected option grant to $0.45 per share while keeping all other terms, including vesting schedules and expiration dates, unchanged under the company’s 2019 Incentive Award Plan. Individual grants include, for example, 1,680,000 stock options now exercisable at $0.45 per share expiring in 2036. These are compensation-related derivative transactions rather than open-market share purchases or sales.
Gossamer Bio, Inc. reported that COO/CFO Bryan Giraudo had several existing stock option awards canceled and reissued as part of a one-time option repricing under the company’s 2019 Incentive Award Plan.
The repricing, effective March 19, 2026, reduced the exercise price of these options to $0.45 per share from prior exercise prices ranging from $0.838 to $2.88, while keeping all other terms, including vesting schedules and option terms, unchanged. These are compensation-related derivative transactions and do not involve open-market purchases or sales of common stock.
Gossamer Bio EVP Christian Waage reported a one-time stock option repricing and related option grants and cancellations. Effective as of March 19, 2026, the company approved an option repricing that reduced the exercise price of certain outstanding options to $0.45 per share under its 2019 Incentive Award Plan.
On that date, Waage received multiple new stock option awards with an exercise price of $0.45 covering an aggregate of 2,065,584 shares of common stock, while an equal number of higher-priced options with exercise prices ranging from $0.838 to $2.88 per share were surrendered to the issuer.
All other terms of the repriced options, including vesting schedules and expiration dates through 2036, remain in effect and continue to be tied to Waage’s ongoing service with Gossamer Bio.
Robert Paul Smith Jr., identified as an Officer (Chief Commercial Officer) of Gossamer Bio, Inc. (GOSS), reported a securities acquisition on 10/01/2025. The filing shows an award of 162,500 performance stock units issued at $0 that will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant, and subject to his continuous service to the company. The filing also discloses 25,000 shares held indirectly by a family trust. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact on 10/02/2025.
Christian Waage, Executive Vice President, Tech Ops and Admin at Gossamer Bio, Inc. (GOSS), received a performance stock unit award of 125,000 shares on 10/01/2025. The award has a $0 purchase price and will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant, subject to continuous service. Following the grant, Mr. Waage is reported to beneficially own 710,934 shares directly, plus 45,892 shares held by a family trust and 22,222 held in a trust for his son. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Gossamer Bio, Inc. (GOSS) Chief Operating and Financial Officer Bryan Giraudo reported an award of 181,250 performance stock units on 10/01/2025. The award is a non‑cash grant that will vest in full upon the earlier of: approval of a new drug application for seralutinib or a change in control, provided vesting occurs on or before the fourth anniversary of the grant and the reporting person remains in continuous service. Following the reported grant, Mr. Giraudo beneficially owns 273,987 shares directly and 480,010 shares indirectly through a family trust, for combined reported beneficial ownership disclosed on the form.
Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc. (GOSS), reported receiving a performance stock unit award of 162,500 common stock units on 10/01/2025. The award carries a $0 purchase price and will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, provided vesting occurs on or before the fourth anniversary of the grant date and subject to the reporting person’s continuous service. After the reported transaction, the filing shows 369,356 shares beneficially owned directly and 2,539 shares beneficially owned indirectly through a family trust. The filing was signed by an attorney-in-fact on 10/02/2025.
Hasnain Faheem, President & CEO and a director of Gossamer Bio, Inc. (GOSS), reported a non‑derivative acquisition dated 10/01/2025 of 437,500 performance stock units at a reported price of $0. After the award, the filing shows 557,793 shares beneficially owned directly and 5,408,073 shares beneficially owned indirectly through a family trust. The performance stock units will vest in full upon the earlier of the approval of a new drug application for seralutinib or a change in control, in either case on or before the fourth anniversary of the grant date, and are subject to the reporting person’s continuous service to the issuer. The Form 4 was signed on 10/02/2025 by an attorney‑in‑fact.
Caryn Peterson, Executive Vice President, Regulatory Affairs of Gossamer Bio, Inc. (GOSS), reported the acquisition of 125,000 performance stock units on 10/01/2025. The award is a performance stock unit grant that vests in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant date, and is subject to the reporting person’s continuous service. After the transaction the reporting person beneficially owns 174,833 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.